Biomerica, Inc. (BMRA)
| Market Cap | 8.42M +4.0% |
| Revenue (ttm) | 4.45M -16.2% |
| Net Income | -3.78M |
| EPS | -1.30 |
| Shares Out | 4.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,303 |
| Open | 1.860 |
| Previous Close | 1.890 |
| Day's Range | 1.850 - 1.860 |
| 52-Week Range | 1.450 - 3.213 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 23, 2026 |
About BMRA
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specifi... [Read more]
Financial Performance
In fiscal year 2026, Biomerica's revenue was $4.45 million, a decrease of -16.16% compared to the previous year's $5.31 million. Losses were -$3.78 million, -24.09% less than in 2025.
Financial StatementsNews
Biomerica files $250M mixed securities shelf
14:57 EDT Biomerica (BMRA) files $250M mixed securities shelf
Biomerica files to sell 1.4M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.4M shares of common stock. The company is not selling any…
Biomerica Reports Fiscal 2026 Year-End Financial Results
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2026 (“Fiscal 2026”).
Biomerica prices 1.39M shares at $1.60 in private placement
Biomerica (BMRA) announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the company’s common s...
Biomerica engages B. Riley as its exclusive financial advisor
Biomerica (BMRA) announced that it has engaged B. Riley as its exclusive financial advisor in connection with the evaluation and potential pursuit of potential strategic opportunities. Under the engag...
Biomerica Announces $2.23 Million Financing
IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the “Company”), a developer and manufacturer of diagnostic test systems, today announced that it has en...
Biomerica enters master services agreement with life sciences company
Biomerica (BMRA) announced it has entered into a master services agreement with a confidential life sciences company to develop proprietary in vitro diagnostic assays. The engagement carries an initia...
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capital-efficient, parallel revenue stream al...
Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago Real-world clinical experie...
Biomerica announces MAC confirms inFoods IBS test is eligible for coverage
Biomerica (BMRA) announced that the Medicare Administrative Contractor, MAC, responsible for processing inFoods IBS claims has confirmed to the Company’s CLIA-certified laboratory partner, Ethos Labor...
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate Company and Laboratory Partner Believe Properly Documented Claim...
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated ...
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today report...
Biomerica receives first commercial order for Hp Detect
Biomerica (BMRA) announced it has received its first commercial order for Hp Detect, its Helicobacter pylori diagnostic stool antigen test, from one of the largest clinical laboratory chains operating...
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first ...
Biomerica receives MHRA registration for hp+detect
Biomerica (BMRA) announced that it has received official registration from the UK Medicines & Healthcare products Regulatory Agency, MHRA, for its hp+detect diagnostic test that detects Helicobacter p...
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic lab...
Biomerica reports responder analysis results from study of inFoods IBS
Biomerica (BMRA) announced responder analysis results from its ongoing real-world study of inFoods IBS. The data demonstrates that a majority of patients achieved clinically meaningful reductions in b...
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with th...
Biomerica announces Vietnam approved EZ Detect for nationwide distribution
Biomerica (BMRA) announced that Vietnam’s Hanoi Department of Health has officially approved the EZ Detect colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biom...
Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially...
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Compa...
Biomerica announces CMS Medicare payment rate of $300 for IBS test
Biomerica (BMRA) announced that the Centers for Medicare & Medicaid Services, CMS, has issued its final pricing determination for the company’s inFoods IBS test, establishing a national Medicare payme...
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the Centers for Medicare & Medicaid Services ...
Biomerica’s complete screening test portfolio authorized in Egypt
Biomerica (BMRA) announced today that the Egyptian Drug Authority has granted authorization for Biomerica’s complete portfolio of rapid tests for conditions associated with cancers and chronic disease...